T
Tanya Taran
Researcher at Novartis
Publications - 28
Citations - 3721
Tanya Taran is an academic researcher from Novartis. The author has contributed to research in topics: Everolimus & Cancer. The author has an hindex of 10, co-authored 28 publications receiving 2378 citations.
Papers
More filters
Journal ArticleDOI
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude,Theodore W. Laetsch,Jochen Buechner,S. Rives,Michael Boyer,Henrique Bittencourt,Peter Bader,Michael R. Verneris,Heather E. Stefanski,G.D. Myers,Muna Qayed,B. De Moerloose,Hidefumi Hiramatsu,Krysta Schlis,Kara L. Davis,Paul L. Martin,Eneida R. Nemecek,Gregory A. Yanik,Christina Peters,André Baruchel,Nicolas Boissel,Francoise Mechinaud,Adriana Balduzzi,Joerg Krueger,Carl H. June,Bruce L. Levine,Patricia A. Wood,Tanya Taran,Mimi Leung,Karen Thudium Mueller,Yiyun Zhang,Kapildeb Sen,David Lebwohl,Michael A. Pulsipher,Stephan A. Grupp +34 more
TL;DR: In this global study of CAR T‐cell therapy, a single infusion of tisagenlecleucel provided durable remission with long‐term persistence in pediatric and young adult patients with relapsed or refractory B‐cell ALL, with transient high‐grade toxic effects.
Journal ArticleDOI
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
Dennis J. Slamon,Patrick Neven,S Chia,Guy Jerusalem,M. De Laurentiis,S-A. Im,K. Petrakova,G. Valeria Bianchi,Miguel Martin,Arnd Nusch,Gabe S. Sonke,L. de la Cruz-Merino,JT Beck,Y. Ji,Craig Wang,U. Deore,Arunava Chakravartty,Juan Pablo Zarate,Tanya Taran,Peter A. Fasching +19 more
TL;DR: The MONALEESA-3 trial as discussed by the authors showed that ribociclib plus fulvestrant demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+) advanced breast cancer (ABC).
Journal ArticleDOI
Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.
Gabriel N. Hortobagyi,Martine Piccart-Gebhart,Hope S. Rugo,Howard A. Burris,Mario Campone,Shinzaburo Noguchi,Alejandra T. Perez,Ines Deleu,Mikhail Shtivelband,Louise Provencher,Norikazu Masuda,Shaker R. Dakhil,Ian Churchill Anderson,David Chen,Amy Damask,Alan Huang,Robert E McDonald,Tanya Taran,Tarek Sahmoud,José Baselga +19 more
TL;DR: EVE plus exemestane (EXE) more than doubled progression-free survival while maintaining quality of life vs EXE alone in postmenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer (BOLERO-2 phase III; NCT00863655).
Journal ArticleDOI
LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
Gabriel N. Hortobagyi,Salomon M. Stemmer,H. A. Burris,Y-S Yap,Gabe S. Sonke,Lowell L. Hart,M. Campone,K. Petrakova,EP Winer,Wolfgang Janni,Pierfranco Conte,David Cameron,F Andre,CL Arteaga,Juan Pablo Zarate,Arunava Chakravartty,Tanya Taran,F. Le Gac,P. Serra,Joyce A. O'Shaughnessy +19 more
Journal ArticleDOI
Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).
Ruth O'Regan,Mustafa Ozguroglu,Fabrice Andre,Masakazu Toi,Guy Jerusalem,Sharon Wilks,Claudine Isaacs,Binghe Xu,Norikazu Masuda,Francis P. Arena,Denise A. Yardley,Yoon Sim Yap,Pabak Mukhopadhyay,Shyanne Douma,Mona El-Hashimy,Tanya Taran,Tarek Sahmoud,David Lebwohl,Luca Gianni +18 more
TL;DR: The international BOLERO-3 phase 3 study is being conducted to evaluate the addition of EVE to TRAS plus vinorelbine to restore sensitivity to and enhance efficacy of human epidermal growth factor receptor 2 (HER2)-targeted therapy.